Valeritas hauls in $100M for insulin device

Valeritas has secured $100 million in financing to market the V-Go device.--Courtesy of Valeritas

New Jersey's Valeritas has secured up to $100 million in structured debt financing, cash the company will use to sell its FDA-cleared and CE marked V-Go insulin device.

Capital Royalty is behind the cash infusion, which Valeritas said will help it expand its share of the Type 2 diabetes market. V-Go is a fully disposable delivery device that metes out a continuous rate of insulin for 24 hours with on-demand mealtime dosing, the company said, providing an alternative for patients who need multiple insulin injections per day. In 2011, the FDA cleared V-Go to deliver Novo Nordisk's ($NVO) NovoLog insulin treatment.

The insulin device world is more than a little top heavy, with the likes of Johnson & Johnson ($JNJ), Abbott Laboratories ($ABT) and Roche ($RHHBY) controlling major shares of the market. V-Go's ease of use and combination of capabilities, however, make it a unique offering, Valeritas said, and, in putting up $100 million, Capital Royalty believes the device could take off.

"The V-Go is unlike anything else on the insulin-delivery market for patients with Type 2 diabetes," Capital Royalty Chairman Charles Tate said in a statement. "We see great long-term potential in the V-Go, and our investment in Valeritas aligns with our continued focus on building customized financing solutions for healthcare companies with innovative commercial technologies."

Last month, Capital Royalty inked a similar deal with Massachusetts' Good Start Genetics, providing up to $28 million to help the company expand its sequencing-based carrier screening technology, and the firm has pieced together an $805 million fund tabbed for emerging medical device and biotech companies.

For Valeritas, the structured debt follows the $150 million in equity financing it raised in 2011. The company has also developed the h-Patch for the delivery of non-insulin compounds, the Mini-Ject pre-filled needle-free delivery system and the Micro-Trans transdermal delivery patch.

- read the announcement

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.